Join us on Tuesday July 16 to learn the principles of DyNAbind DNA-Encoded Library drug discovery and preview of the company’s new off-the-shelf offering.
Click the button below to register
16 July 3.00pm (BST)
This webinar will cover the principles underlying DNA-Encoded Library (DEL) based drug discovery along with the history of the technology’s development. DyNAbind’s emphasis on fragment-based DEL discovery will then be discussed, followed by the presentation of a case study which goes from initial DEL screen through to kinetic hit validation and fragment-linking off-DNA before verifying hit compound performance in an inhibition assay. The webinar will conclude with the presentation of DyNAbind’s commercially available off-the-shelf fragment-based library.
- By the end of this webinar you will be able to understand the concepts behind DNA-Encoded Library drug discovery
- By attending this webinar you will learn how fragment-based drug discovery can be combined with large library screening
- By the end of this webinar you’ll have a better idea of whether a DEL approach is something that can make sense in your group
This webinar is brought in association with MilliporeSigma.
Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community – and through that, we aim to accelerate access to better health for people everywhere.
We provide scientists and engineers with best-in-class lab materials, technologies and services. With the 2015 combination of EMD Millipore and Sigma-Aldrich, we now have a broad portfolio of 300,000 products and an expanded global footprint.
We are dedicated to making research and biotech production simpler, faster and safer.
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
Speaker: Michael Thompson, CEO & co-founder of DyNAbind
Mike Thompson is a chemist by training and originally from Florida. Mike moved to Germany in 2011 to do his doctoral work in the lab of Prof. Yixin Zhang at the TU Dresden’s B CUBE Center for Molecular Bioengineering. He has served as CEO of DyNAbind since the company’s foundation in 2017.
Speaker: Francesco Reddavide, Director of Research & Development at DyNAbind
Francesco Reddavide is originally from Italy, where he studied biotechnology before moving to do his PhD in Germany in the lab of Prof. Yixin Zhang at the TU Dresden’s B CUBE Center for Molecular Bioengineering. Since DyNAbind’s foundation in 2017, Francesco has been Director of research & development.
Speaker: John Fetter, Product Manager of Emerging Chemical Synthesis at Merck
John Fetter has a Ph.D. in biochemistry and has worked in pharmaceutical and biotech drug discovery. He is currently a Product manager for emerging chemical synthesis at Merck KGaA, Darmstadt, Germany. He has developed a portfolio of bioconjugation products and recently worked on bringing in the DEL technology.
Moderator: Benjamin Valsler, Digital editor, Chemistry World magazine
Ben is the digital editor of Chemistry World magazine, producing video and podcasts to accompany the magazine and website. Prior to joining the Royal Society of Chemistry, he was the producer of the award-winning Naked Scientists, making local and national radio programmes for the BBC, the Australian Broadcasting Corporation and Primedia in South Africa.
[Embedded content below must be updated to have correct link in <iframe> and also appropriate pixel height for each media break point, dependent on the form itself.]